Lupus & antiphospholipid syndrome
Bridging Generations: Leveraging Technology and Artificial Intelligence for Better Research, Outreach, and Daily Practice
Authors' conclusion
In addition to clinical efficacy, in this preliminary cohort, CD19 CAR T cell treatment improves QOL in patients with SLE and may substantially reduce the direct socioeconomic burden associated with active disease by > 90%.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) (7 female, 1 male; age range 19–38 years) who received chimeric antigen receptor (CAR) T cell therapy and were followed for > 2 years, German healthcare service7 female, 1 male
- Participants
- 8 patients
- Exposure
- Quality of life (QOL) and direct healthcare costs before vs after CD19 CAR T cell therapy
- Outcome
- Physical and mental health (36-item Short Form Health Survey) and annual direct healthcare costs
- Follow-up
- 1 year after treatment
Methodological detailspreliminary analysis, before and after treatment
- Preliminary analysis
- Before and after treatment
Main finding
As reported in the abstract
QOL (SF-36)
Physical health, before → after
from 22.4% to 75.5%
Mental health, before → after
from 24.7% to 63%
Observational data: associations, not effects.
Further findings
| Outcome | Before CAR T | After CAR T |
|---|---|---|
| Annual direct healthcare costs | €29,672/year | €3094/year |
| USD | US $34,353/year | $3582/year |
Original publication
Bridging Generations: Leveraging Technology and Artificial Intelligence for Better Research, Outreach, and Daily Practice. J Rheumatol. Published 1 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →